CIT can broadcast your seminar, conference or meeting live to a world-wide
audience over the Internet as a real-time streaming video. The event can
be recorded and made available for viewers to watch at their convenience
as an on-demand video or a downloadable podcast. CIT can also broadcast
NIH-only or HHS-only content.
Eleventh annual Philip S. Chen, Jr., Ph.D. Distinguished Lecture on Innovation and Technology Transfer
John J. O'Shea graduated Phi Beta Kappa from St. Lawrence University
with a Bachelor of Science degree, and then gained a Doctor of
Medicine degree from the University of Cincinnati. He carried out a
residency in Internal Medicine at the State University of New York
Upstate Medical University and did subspecialty training at the National
Institute of Allergy and Infectious Diseases, NIH.
Dr. O’Shea has made fundamental discoveries related to the basic
mechanisms underlying cytokine signal transduction, molecules that are
critical for the development and functioning of the immune system. He
and his colleagues first cloned the human tyrosine kinase JAK3 and
discovered its role in signaling by interleukin-2. These insights led to the
discovery of JAK3 mutations as a cause of severe combined immunodeficiency.
The demonstration of the role of Janus kinases in cytokine signaling
led Dr. O’Shea and his colleagues to propose that targeting JAKs
would represent a new class of immunomodulatory drugs. He was
awarded a U.S. patent for his work on Janus family kinase inhibitors and
developed a Cooperative Research and Development Agreement with
the pharmaceutical company Pfizer, which generated one such compound.
This drug, tofacitinib, is now approved for the treatment of
rheumatoid arthritis and is the first oral therapy for rheumatoid arthritis
approved in a decade.
Dr. O'Shea has received numerous awards, including: the NIH Director's
Award four times, the US Public Health Service Physician Researcher of
the Year Award, the Irish Immunology Public Lecture Award, the Arthritis
Foundation's Howley Prize, the Ross Prize in Molecular Medicine, the
Daniel Drake Prize, as well as Danny Thomas, Lockey, Cochrane,
Talmadge and Stone lectureships. He was nominated to give a lecture at
the Nobel Forum and was a Distinguished Lecturer at this year’s American
Association of Immunology annual meeting. He was designated as
one the “The World’s Most Influential Scientific Minds 2003-2014” by
Thompson Reuters. Dr. O’Shea is a member of the American Association
of Physicians, a Fellow of the American Association for the Advancement
of Science (AAAS) and a member of the National Academy of Medicine.
He has published more than 300 peer-reviewed articles and has been on
the editorial boards of many journals including the Journal of Biological
Chemistry, Blood, Journal of Immunology, Immunity and the Journal of
Experimental Medicine. Dr. O’Shea is a founding Director of the
NIH/Oxford Graduate Program in Biomedical Science and a Professor of
Pathology at the University of Pennsylvania.
John J. O'Shea, M.D., Scientific Director and Senior Investigator, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH